Synact Pharma: Q4 comment
Research Note
2020-02-11
10:10
As expected, Synact’s interim report for the fourth quarter included no surprises. We give a brief comment on the financial situation and the anticipated news flow going forward.
LS
Ludvig Svensson
Disclosures and disclaimers